Findings

What do systematic reviews say?

4,710 questions · 14,842 findings · 1,394 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2,880 · 19.4%GRADE not reported 1,413 · 9.5%Very low 3,103 · 20.9%Low 3,870 · 26.1%Moderate 2,663 · 17.9%High 913 · 6.2%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Homeopathic medicinal products (non‐individualised treatment) vs placebo or usual care

Disease severity · children aged up to 16 years with ARTIs

The review found no eligible studies for this question.

1 finding from 1 review

Homeopathic medicinal products for preventing and treating acute respiratory tract infections in children 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Homeopathic medicinal products (non‐individualised treatment) vs placebo or usual care

Recurrence of ARTI · children aged up to 16 years with ARTIs

Homeopathic medicinal products (non‐individualised treatment) showed no clear difference in recurrence of ARTI compared with placebo or usual care (low certainty).

1 finding from 1 review

Homeopathic medicinal products for preventing and treating acute respiratory tract infections in children 2022 · Cochrane Headline outcomes only
OR 0.6 [0.21, 1.72]
3 studies · 735 participants
Low

Homeopathic medicinal products (non‐individualised treatment) vs placebo or usual care

Days off work for parents · children aged up to 16 years with ARTIs

The review found no eligible studies for this question.

1 finding from 1 review

Homeopathic medicinal products for preventing and treating acute respiratory tract infections in children 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Homeopathic medicinal products (non‐individualised treatment) vs placebo or usual care

Need for antibiotics · children aged up to 16 years with ARTIs

The review found no eligible studies for this question.

1 finding from 1 review

Homeopathic medicinal products for preventing and treating acute respiratory tract infections in children 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Any glucocorticoid vs no glucocorticoids or placebo

Live birth rate per couple · assisted reproduction technology cycles

It is very uncertain whether glucocorticoids changes live birth rate per couple compared with no glucocorticoids or placebo (very low certainty).

1 finding from 1 review

Peri‐implantation glucocorticoid administration for assisted reproductive technology cycles 2022 · Cochrane Headline outcomes only
OR 1.37 [0.69, 2.71]
2 studies · 366 participants
Very low

Any glucocorticoid vs no glucocorticoids or placebo

Miscarriage · assisted reproduction technology cycles

It is very uncertain whether glucocorticoids changes miscarriage rate per couple compared with no glucocorticoids or placebo (very low certainty).

1 finding from 1 review

Peri‐implantation glucocorticoid administration for assisted reproductive technology cycles 2022 · Cochrane Headline outcomes only
OR 1.09 [0.63, 1.87]
6 studies · 821 participants
Very low

Any glucocorticoid vs no glucocorticoids or placebo

Ectopic pregnancy rate per couple · assisted reproduction technology cycles

It is very uncertain whether glucocorticoids changes incidence of ectopic pregnancies per couple compared with no glucocorticoids or placebo (very low certainty).

1 finding from 1 review

Peri‐implantation glucocorticoid administration for assisted reproductive technology cycles 2022 · Cochrane Headline outcomes only
OR 2.28 [0.33, 15.62]
3 studies · 320 participants
Very low

Any glucocorticoid vs no glucocorticoids or placebo

Incidence of OHSS per couple (mild‐severe) · assisted reproduction technology cycles

It is very uncertain whether glucocorticoids changes incidence of OHSS per couple (mild–severe) compared with no glucocorticoids or placebo (very low certainty).

1 finding from 1 review

Peri‐implantation glucocorticoid administration for assisted reproductive technology cycles 2022 · Cochrane Headline outcomes only
OR 1.07 [0.6, 1.9]
3 studies · 370 participants
Very low

Any glucocorticoid vs no glucocorticoids or placebo

Multiple pregnancy rate · assisted reproduction technology cycles

It is very uncertain whether glucocorticoids changes incidence of multiple pregnancies per couple compared with no glucocorticoids or placebo (very low certainty).

1 finding from 1 review

Peri‐implantation glucocorticoid administration for assisted reproductive technology cycles 2022 · Cochrane Headline outcomes only
OR 0.86 [0.33, 2.2]
4 studies · 504 participants
Very low

Any glucocorticoid vs no glucocorticoids or placebo

Ongoing pregnancy rate per couple · assisted reproduction technology cycles

It is very uncertain whether glucocorticoids changes ongoing pregnancy rate per couple compared with no glucocorticoids or placebo (very low certainty).

1 finding from 1 review

Peri‐implantation glucocorticoid administration for assisted reproductive technology cycles 2022 · Cochrane Headline outcomes only
OR 1.19 [0.8, 1.76]
3 studies · 476 participants
Very low

Any glucocorticoid vs no glucocorticoids or placebo

Clinical pregnancy rate · assisted reproduction technology cycles

Glucocorticoids showed no clear difference in clinical pregnancy rate per couple –pregnancy rate per couple… compared with no glucocorticoids or placebo (low certainty).

4 findings from 1 review

Peri‐implantation glucocorticoid administration for assisted reproductive technology cycles 2022 · Cochrane Headline outcomes only
OR 1.17 [0.95, 1.44]
13 studies · 1967 participants
Low
Peri‐implantation glucocorticoid administration for assisted reproductive technology cycles 2022 · Cochrane Headline outcomes only
OR 1.2 [0.87, 1.67]
6 studies · 780 participants
Very low
Peri‐implantation glucocorticoid administration for assisted reproductive technology cycles 2022 · Cochrane Headline outcomes only
OR 1.15 [0.87, 1.5]
7 studies · 1187 participants
Very low

Show 1 more finding

Peri‐implantation glucocorticoid administration for assisted reproductive technology cycles 2022 · Cochrane Headline outcomes only
OR 1.17 [0.9, 1.52]
7 studies · 1246 participants
Very low

Any glucocorticoid vs no glucocorticoids or placebo

Clinical pregnancy rate per couple – subgroup IVF · assisted reproduction technology cycles

It is very uncertain whether glucocorticoids changes clinical pregnancy rate per couple – subgroup IVF compared with no glucocorticoids or placebo (very low certainty).

1 finding from 1 review

Peri‐implantation glucocorticoid administration for assisted reproductive technology cycles 2022 · Cochrane Headline outcomes only
OR 1.44 [1, 2.08]
5 studies · 724 participants
Very low

Any glucocorticoid vs no glucocorticoids or placebo

Clinical pregnancy rate per couple – subgroup ICSI · assisted reproduction technology cycles

It is very uncertain whether glucocorticoids changes clinical pregnancy rate per couple – subgroup ICSI compared with no glucocorticoids or placebo (very low certainty).

1 finding from 1 review

Peri‐implantation glucocorticoid administration for assisted reproductive technology cycles 2022 · Cochrane Headline outcomes only
OR 1.08 [0.81, 1.42]
6 studies · 992 participants
Very low

Interventions (vitamin B1, mefenamic acid, tranexamic acid) vs placebo or active comparators (desmopressin, sodium diclofenac, flavonoids)

Interventions versus comparisons

The review found no eligible studies for this question.

1 finding from 1 review

Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Interventions (vitamin B1, mefenamic acid, tranexamic acid) vs placebo or active comparators (desmopressin, sodium diclofenac, flavonoids)

Duration of bleeding

1 finding from 1 review

Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 38 participants
Very low

Interventions (vitamin B1, mefenamic acid, tranexamic acid) vs placebo or active comparators (desmopressin, sodium diclofenac, flavonoids)

Side effects: gastrointestinal disturbances (diarrhoea, lower abdominal pain), headache and sweating

It is very uncertain whether interventions (vitamin B1, mefenamic acid, tranexamic acid) changes side effects: gastrointestinal disturbances (diarrhoea, lower… compared with placebo or active comparators (desmopressin, sodium diclofenac,… (very low certainty).

1 finding from 1 review

Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
OR 4.69 [1.2, 18.44]
1 study · 38 participants
Very low

Interventions (vitamin B1, mefenamic acid, tranexamic acid) vs placebo or active comparators (desmopressin, sodium diclofenac, flavonoids)

Menstrual blood loss PBAC score

2 findings from 1 review

Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 100 participants
Low
Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 24 participants
Very low

Interventions (vitamin B1, mefenamic acid, tranexamic acid) vs placebo or active comparators (desmopressin, sodium diclofenac, flavonoids)

Menstrual blood loss Number of pads (diary record)

2 findings from 1 review

Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 100 participants
Low
Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 110 participants
Low

Interventions (vitamin B1, mefenamic acid, tranexamic acid) vs placebo or active comparators (desmopressin, sodium diclofenac, flavonoids)

Duration of bleeding Number of bleeding days

2 findings from 1 review

Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 100 participants
Low
Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 290 participants
Very low

Interventions (vitamin B1, mefenamic acid, tranexamic acid) vs placebo or active comparators (desmopressin, sodium diclofenac, flavonoids)

Adverse effects: headache

Interventions (vitamin B1, mefenamic acid, tranexamic acid) showed no clear difference in side effects: headache compared with placebo or active comparators (desmopressin, sodium diclofenac,… (low certainty).

1 finding from 1 review

Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
OR 0.58 [0.18, 1.92]
1 study · 100 participants
Low